The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
Open accessAbstract
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing. The mean absolute oral bioavailability of vortioxetine is 75%. No food effect on pharmacokinetics was observed. Vortioxetine is metabolized by cytochrome P450 enzymes and subsequently by uridine diphosphate glucuronosyltransferase. The major metabolite is pharmacologically inactive, and the minor pharmacologically active metabolite is not expected to cross the blood-brain barrier, making the parent compound primarily responsible for in-vivo activity. No clinically relevant differences were observed in vortioxetine exposure by sex, age, race, body size, and renal or hepatic function. Dose adjustment is only recommended for cytochrome P450 2D6 poor metabolizers based on polymorphism of the cytochrome P450 enzymes involved. Similarly, except for bupropion, a strong cytochrome P450 2D6 inhibitor, and rifampin, a broad cytochrome P450 inducer, co-administration of other drugs evaluated did not affect the vortioxetine exposure or safety profile in any clinically meaningful way. Pharmacodynamic studies demonstrated that vortioxetine achieved high levels of serotonin transporter occupancy in relevant brain areas, affected neurotransmitter levels in the cerebrospinal fluid, and modified abnormal resting state networks in the brain over the therapeutic dose range. Overall, vortioxetine can be administered in most populations studied to date without major dose adjustments; however, dose adjustments should be considered on a patient-by-patient basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P., Chen, Y., & Thase, M. E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07470 · Cited by 150
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
Stenkrona, P., Halldin, C., & Lundberg, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.002 · Cited by 78 · cited 2×
“The occupancy of vortioxetine at SERT in different brain regions was studied in two positron emission tomography studies using (11)C-MADAM, (11)C-WAY100635, or (11)C-DASB ligands [44, 45].”
MethodThe Clinical Pharmacokinetics of Lu AA 21004 and its Major Metabolite in Healthy Young Volunteers
Areberg, J., Søgaard, B., & Højer, A. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00886.x · Cited by 69 · cited 4×
“Vortioxetine is almost entirely eliminated by the liver; renal clearance of the parent drug contributed to\1% of CL/F, while hepatic clearance accounted for the other 99% [21].”
BackgroundInfluentialSelf-citation
Cited by
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
The role of reelin in the pathological mechanism of depression from clinical to rodents
Jin, K., Zhang, S., Jiang, C., Liu, R., Chen, B., Zhao, H., Zhang, Q., Shen, Z., Xu, P., Hu, X., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114838 · Cited by 13
Zhang, Y., Lai, S., Zhang, J., Wang, Y., Zhao, H., He, J., Huang, D., Chen, G., Qi, Z., Chen, P., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.272 · Cited by 11
Self-citation
Metadata
- Authors
- Chen, G., Højer, A.-M., Areberg, J., & Nomikos, G.
- Venue
- Clinical Pharmacokinetics
- Published
- 2017-11-30
- Volume
- 57
- Issue
- 6
- Pages
- 673-686
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2775576435
- Cited by
- 164
- References
- 13
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. https://app.cochat.ai/papers/10.1007/s40262-017-0612-7
- The paper
- Chen, G., Højer, A.-M., Areberg, J., & Nomikos, G. (2018). Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-017-0612-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.